News

RESTASIS is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, a type of

This novel supplement can be added to an optimized serum free media for greater protein yield or used as a culture media in place of FBS or other

The company will interpret samples in rare disease and cancer as part of the project, which is being undertaken by Genomics England. The project intends to sequence 100,000

Thetanix is designed to treat paediatric Crohn’s disease (PCD), which is a chronic inflammatory bowel disease that causes inflammation, or swelling, across the lining of the digestive tract,

The Astellas dermatology portfolio consists of prescription and over-the-counter products, including Protopic, Locoid and Locobase, and Zineryt to treat eczema, acne and skin infections. The transaction, which is

NGP 555 is a first in class small molecule for the treatment and prevention of Alzheimer’s disease. NGP 555 is an amyloid modulator showing good brain penetration in

US-based Ocata develops and commercializes regenerative ophthalmology therapeutics. The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology programs and involve development of therapies to treat

Cotellic and Zelboraf are not used to treat melanoma with a normal BRAF gene. Cotellic is Genentech’s seventh new medicine approved by the FDA in the past five

MRL Ventures, a venture fund of Merck, and JAFCO led the Series C preferred stock financing round. Brace Pharma Capital and MP Healthcare Venture Management were the other